Sumitomo Pharma America has secured United States Food and Drug Administration orphan drug designation for enzomenib, also known as DSP-5336, as a potential treatment for acute lymphoblastic leukemia. The regulatory decision broadens the formal development framework around the investigational oral menin inhibitor, which is already being evaluated in patients with relapsed or refractory acute leukemia.
The designation does not represent approval, establish clinical effectiveness or confirm that enzomenib will ultimately reach the market. It does, however, give Sumitomo Pharma access to development incentives associated with therapies for rare diseases while strengthening the regulatory foundation for a programme that has moved into Phase 2 development.
Enzomenib is designed to inhibit the interaction between menin and the lysine methyltransferase 2A protein, commonly referred to as KMT2A. That interaction supports abnormal gene-expression programmes associated with certain genetically defined acute leukemias, particularly cancers carrying KMT2A rearrangements or nucleophosmin 1 mutations.
The central question is now whether the encouraging activity reported from early clinical development can be reproduced in a larger, more focused and potentially registration-enabling population. The orphan designation may improve the programme’s development economics, but enzomenib’s clinical prospects will still depend on response durability, safety, biomarker selection and the quality of evidence produced by its pivotal Phase 2 study.
Why does FDA orphan drug designation matter for enzomenib’s development in acute lymphoblastic leukemia?
The United States Food and Drug Administration grants orphan drug designation to drugs and biologics being developed for rare diseases or conditions. The programme can provide benefits including tax credits for qualifying clinical research, exemption from certain regulatory fees and the possibility of seven years of market exclusivity after approval for the designated indication.
These incentives are intended to make development more viable in diseases where relatively small patient populations can complicate enrolment, increase clinical costs and limit the commercial return available to drug developers. For enzomenib, the designation could therefore support a development pathway in acute lymphoblastic leukemia that would otherwise need to compete for resources with larger oncology indications.
The distinction between designation and approval remains important. Orphan status does not mean that the FDA has concluded enzomenib is effective, safer than competing therapies or likely to be approved. The decision primarily recognises the rarity of the proposed indication and the eligibility of the development programme for specific regulatory incentives.
Sumitomo Pharma previously obtained FDA orphan drug designation for enzomenib in acute myeloid leukemia in June 2022. The agency subsequently granted Fast Track designation in June 2024 for relapsed or refractory acute myeloid leukemia with KMT2A rearrangements or NPM1 mutations. Japan’s Ministry of Health, Labour and Welfare also granted orphan designation in September 2024 for the biomarker-defined acute myeloid leukemia population.
The addition of acute lymphoblastic leukemia indicates that Sumitomo Pharma sees a potentially broader role for menin inhibition across acute leukemias driven by susceptible molecular abnormalities. Whether that strategy succeeds will depend on showing that the biological rationale translates into clinically meaningful and durable responses in each disease setting.
How is enzomenib designed to interfere with the biology of biomarker-defined acute leukemia?
Menin is a nuclear scaffold protein involved in gene regulation, cell growth, genomic stability and normal blood-cell development. In some leukemias, the interaction between menin and KMT2A contributes to the maintenance of abnormal gene-expression patterns that allow immature malignant cells to proliferate.
Enzomenib is an orally administered small molecule intended to disrupt that interaction. Preclinical research reported by Sumitomo Pharma found that the compound inhibited the growth of human acute leukemia cell lines carrying KMT2A rearrangements or NPM1 mutations.
The company has also reported reductions in the expression of leukemia-associated genes including HOXA9 and MEIS1, together with increased expression of CD11b, a marker associated with cellular differentiation. These findings support the proposed mechanism, under which blocking the menin-KMT2A interaction may encourage malignant cells to move away from an immature, self-renewing state.
Mechanistic plausibility is useful, but it cannot substitute for clinical evidence. Acute leukemia is biologically heterogeneous, and responses observed in laboratory models may not predict the depth or durability of benefit in heavily pretreated patients.
The development strategy consequently depends on molecular selection. By focusing on leukemias carrying KMT2A rearrangements or NPM1 mutations, Sumitomo Pharma is attempting to identify patients whose cancers are more likely to depend on the pathway enzomenib is designed to interrupt.
That biomarker-led approach could improve the probability of observing activity, although it also narrows the addressable population and increases the importance of timely genomic testing. In routine practice, the commercial and clinical use of a future menin inhibitor would require eligible patients to be identified quickly, often when their disease is progressing and treatment options are limited.
What do the available enzomenib clinical results show, and where are the evidence gaps?
Enzomenib has been evaluated in an open-label Phase 1/2 dose-escalation and dose-expansion study involving patients with relapsed or refractory acute leukemia. The study includes acute myeloid leukemia, acute lymphoblastic leukemia and acute leukemia of ambiguous lineage, alongside selected additional hematologic malignancies at certain sites.
The early study was designed to examine safety, pharmacokinetics, pharmacodynamic effects and preliminary clinical activity across escalating and expanded dose groups. It was not a randomised comparison against an established treatment, meaning its response findings cannot show that enzomenib is superior to available therapies.
Sumitomo Pharma reported an updated safety population of 84 patients in October 2025. Acute myeloid leukemia accounted for 79 of those participants, or 94%, which means the disclosed evidence was dominated by acute myeloid leukemia rather than acute lymphoblastic leukemia.
In a 40-patient dose-optimisation population receiving either 200mg or 300mg twice daily, the company reported an objective response rate of 62.5%. The combined rate of complete remission and complete remission with partial haematologic recovery was 37.5%.
Among 12 Japanese participants included in the efficacy analysis, the reported objective response rate was 75%, while the combined complete remission and complete remission with partial haematologic recovery rate was 41.7%. These figures provide an early signal that enzomenib has biological and clinical activity in heavily treated, biomarker-selected acute leukemia.
However, several limitations remain important. The study population was small, non-randomised and heavily weighted towards acute myeloid leukemia. Response rates alone do not establish how long remissions last, whether patients experience improved survival or how enzomenib compares with other menin inhibitors and established salvage treatments.
The new orphan designation specifically covers acute lymphoblastic leukemia, but the publicly disclosed dataset does not yet offer a comparably mature ALL-specific efficacy analysis. The regulatory milestone therefore runs ahead of the available disease-specific clinical evidence.
That is not unusual in orphan-drug development, where designations can be granted before pivotal results become available. It does mean that future ALL data will need to do more than demonstrate occasional responses. The programme will need to clarify which molecularly defined ALL patients benefit, how deep those responses are and whether they remain durable enough to support a favourable benefit-risk assessment.
Why will differentiation syndrome remain a closely watched risk for enzomenib and other menin inhibitors?
Sumitomo Pharma described enzomenib as well tolerated in its disclosed Phase 1/2 analysis and reported no dose-limiting toxicities across the studied dose range. The company also reported a relatively low incidence of treatment-related adverse events.
Differentiation syndrome occurred in 10.7% of the overall safety population and 13.6% of the Japanese population. No reported cases resulted in treatment discontinuation or death in the disclosed analysis.
Differentiation syndrome is a clinically significant risk associated with therapies that cause malignant blood cells to mature rapidly. It can involve fever, fluid accumulation, breathing difficulties, low blood pressure and organ dysfunction. Prompt recognition and management are therefore important.
The presence of differentiation syndrome can also be viewed as evidence that the drug is producing its intended biological effect. Nevertheless, its clinical relevance depends on severity, timing, reversibility and the effectiveness of monitoring and treatment protocols.
Larger studies will provide a clearer view of enzomenib’s safety profile. Investigators and regulators will be particularly interested in severe adverse events, treatment interruptions, dose reductions, discontinuations and deaths, alongside potential cardiac, hepatic or infectious complications.
Safety will also influence combination strategies. Menin inhibitors may eventually be paired with chemotherapy, targeted agents or lower-intensity regimens, but combination development can introduce overlapping toxicities and make it harder to attribute adverse events to a single treatment.
How does the Horizen-1 Phase 2 study move enzomenib closer to a potential registration pathway?
Enzomenib is now listed by Sumitomo Pharma as a Phase 2 oncology programme for acute leukemia. The company is conducting the Horizen-1 study as a registrational Phase 2 monotherapy trial in relapsed or refractory acute leukemia with KMT2A rearrangements or NPM1 mutations.
The trial includes acute myeloid leukemia and acute lymphoblastic leukemia populations. Its design reflects a development model increasingly used in molecularly defined cancers, where high response rates and durable remissions in patients with limited alternatives may support an accelerated regulatory pathway.
Sumitomo Pharma reported in June 2026 that it had enrolled the required number of participants in the KMT2A-rearranged portion of Horizen-1 to allow an interim analysis. The company expects results from that analysis by the end of calendar 2026.
The interim dataset will be a critical test. Regulators will assess not only the proportion of patients responding but also complete remission rates, duration of response, time to response, transfusion independence and the feasibility of using enzomenib as a bridge to stem-cell transplantation.
The representation of acute lymphoblastic leukemia patients will matter particularly after the new orphan designation. A pooled acute leukemia analysis could support the drug’s broader biological rationale, but regulators may still require sufficiently persuasive results within each proposed indication.
Patient eligibility and prior menin inhibitor exposure will also affect interpretation. As more menin inhibitors become available, future trials will increasingly need to address treatment sequencing, resistance mutations and whether one drug retains activity after failure of another agent in the class.
What competitive pressures could shape enzomenib’s prospects in the emerging menin inhibitor market?
Enzomenib is entering a field that has progressed rapidly from scientific concept to regulatory validation. Menin inhibition is no longer an untested approach, following FDA approvals for other members of the class in molecularly defined relapsed or refractory acute myeloid leukemia.
The FDA approved revumenib for relapsed or refractory acute leukemia with KMT2A translocation in 2024 and later expanded its use to relapsed or refractory acute myeloid leukemia with a susceptible NPM1 mutation in October 2025. The agency also approved ziftomenib for relapsed or refractory NPM1-mutated acute myeloid leukemia in November 2025.
Those approvals reduce the biological risk surrounding menin inhibition because they demonstrate that disrupting the pathway can generate clinically meaningful responses. They simultaneously raise the competitive threshold for enzomenib.
Sumitomo Pharma will need to establish where enzomenib fits on efficacy, response durability, safety, drug-interaction management, dosing convenience and activity against resistance mechanisms. Cross-trial comparisons will remain unreliable because studies can differ substantially in patient characteristics, prior treatments, mutation profiles, endpoint definitions and follow-up periods.
The company may ultimately differentiate enzomenib through a broader acute leukemia label, favourable tolerability, activity in acute lymphoblastic leukemia or effective combination regimens. None of those advantages has yet been established.
Commercial positioning could also depend on diagnostic infrastructure. Menin inhibitors are aimed at biomarker-defined populations, making rapid and accurate identification of KMT2A rearrangements and NPM1 mutations essential. Delays in molecular testing could reduce the time available to treat patients with aggressive relapsed disease.
What must Sumitomo Pharma demonstrate before enzomenib can become a meaningful treatment option?
The FDA orphan drug designation gives Sumitomo Pharma a useful development incentive and formally recognises acute lymphoblastic leukemia as a rare indication within enzomenib’s regulatory strategy. It does not remove the programme’s principal clinical uncertainties.
The most immediate requirement is a sufficiently mature dataset from Horizen-1. The study must show that responses are not only frequent but deep and durable, with a safety profile that clinicians can manage in patients who may already have received multiple intensive treatments.
ALL-specific evidence will be particularly important. Most of the publicly described enzomenib experience has come from patients with acute myeloid leukemia, leaving uncertainty over the number, characteristics and outcomes of acute lymphoblastic leukemia participants.
Longer-term development may also require combination studies and earlier-line evaluation. Single-agent activity can establish proof of concept, but the broader therapeutic value of menin inhibition may emerge through combinations designed to deepen remission or reduce the development of resistance.
Sumitomo Pharma has identified enzomenib as one of its priority oncology assets and is seeking an early approval pathway. The company’s pipeline, updated as of July 31, 2026, lists the programme in Phase 2 development for acute leukemia.
The orphan designation therefore adds regulatory support at a strategically useful moment. The decisive milestone will come when the Phase 2 evidence shows whether enzomenib can offer a durable and clinically relevant benefit in the genetically defined ALL and AML populations that Sumitomo Pharma is targeting.
